|Keep an Eye on Allergies This Season||Johnson & Johnson Press Releases|
|Jacksonville, FL (April 17, 2008) ? An estimated 50 million Americans suffer
from the miseries of allergies, with allergic reactions involving the eyes a
common complaint. For many, symptoms of eye allergies can be so
uncomfortable and irritating that they interfere with job performance, impede
leisure-time and sports activities, and curtail vacations.To help allergy sufferers better understand and manage the condition, the
Asthma and Allergy Foundation of America (AAFA), the leading patient
|CLEAN & CLEAR® Introduces SOFT||Johnson & Johnson Press Releases|
|Skillman, NJ (April 15, 2008)? Consumer studies have shown that 84% of
females aged 18 ? 24 began using a facial moisturizer before they turned 18,
which is a telling sign that young women today are very concerned with their
skincare regimen.1 There are an abundance of facial skincare
products for young consumers on the market today, but most address acne and
problem skin, rather than offering a healthy daily regimen for normal skin. For
those young consumers who do not suffer from acne, the skincare ...
|First-Quarter 2008 Financial Results||Johnson & Johnson Press Releases|
|New Brunswick, NJ (April 15, 2008) ? Johnson & Johnson today announced record
sales of $16.2 billion for the first quarter of 2008, an increase of 7.7% as
compared to the first quarter of 2007. Operational growth was 2.6% and
currency contributed 5.1%. Domestic sales were up 2.8%, while international
sales increased 13.7%, reflecting operational growth of 2.4% and a positive
currency impact of 11.3%.
Net earnings and diluted earnings per share for the first quarter of 2008 were
$3.6 billion and ...
|Positive SAPPHIRE Study Published in NEJM||Johnson & Johnson Press Releases|
|Warren, NJ (April 9, 2008) ? According to a study published in The New
England Journal of Medicine this week, three-year data from the Stenting and
Angioplasty with Protection in Patients at High Risk for Endarterectomy
(SAPPHIRE) study in patients with severe blocked carotid arteries, the main
blood vessels in the neck leading to the brain, who underwent carotid artery
stenting (CAS) with the PRECISE® Nitinol Stent and the ANGIOGUARD® Emboli
Capture Guidewire were comparably protected from stroke, he ...
|Therakos, Inc. Receives CE Mark in Europe||Johnson & Johnson Press Releases|
|Ascot, UK (April 14, 2008) ? Therakos, Inc., a pioneer for more
than 20 years in immune cell therapy, announced receipt of a CE Mark in Europe
for THERAKOST? CELLEXT? Photopheresis System, a therapy for the treatment of
patients with immune-mediated diseases such as acute or chronic
graft-versus-host disease (GvHD) and cutaneous T-cell lymphoma (CTCL).
THERAKOS? CELLEX? Photopheresis System is the next generation in a product line
that offers the only validated, automated and integrated systems that a ...
|OneTouch® Laugh & Learn Sweepstakes Award Scholar...||Johnson & Johnson Press Releases|
|Milpitas, CA (April 11, 2008) ? LifeScan, a Johnson & Johnson company
and the maker of OneTouch® Blood Glucose Meters for people with diabetes, has
announced an online sweepstakes that will offer an opportunity for kids with
diabetes to attend a diabetes camp for free this summer. The OneTouch® Laugh
& Learn Sweepstakes, which runs through May 20, is available at www.DiabetesAndKids.com and offers 30
Grand-Prize winners a weeklong stay at a diabetes camp1 of their
choice, selected from a list of camps ...
|ORD To Present Data At Cancer Meeting||Johnson & Johnson Press Releases|
|San Diego, CA (April 11 2008) ? Ortho Biotech Oncology Research &
Development (ORD), a unit of Johnson & Johnson Pharmaceutical Research
& Development, L.L.C., will announce results from studies of three
innovative compounds?Hdm2, c-Met, and HDAC inhibitors?here at the American
Association for Cancer Research (AACR) 2008 Annual Meeting."ORD is a new research and development organization that unites the
biotechnology and pharmaceutical oncology efforts of several Johnson &
Johnson companies with the go ...